The game is afoot in the obesity space as GLP-1 rivals Eli Lilly and Novo Nordisk take their showdown to a new level. Lilly ...

Three Motley Fool contributors think they've found no-brainer healthcare stocks to buy in May. Here's why they picked Eli ...

After taking part in a landmark case against the manufacturers of the synthetic hormone DES, she represented many other ...

The FDA accepted Novo Nordisk's NDA for an oral formulation of Wegovy. The agency is expected to release its verdict on the ...

Our writer explains why he just added to a big loser to his Stocks and Shares ISA portfolio, despite it going against one of ...

These three stocks could potentially help investors create a stable – and growing – stream of passive income in the years ...

The pharma industry’s reputation dropped slightly again among patient groups, largely due to drug pricing issues.

Key points A 28-year-old man with cocaine and alcohol use disorders presented to the emergency department with a 2-month history of worsening shortness of breath, orthopnea, and fatigue. His medical ...

The first nonstop Aer Lingus flight from Dublin, Ireland landed Saturday night, but the long-term impact is just starting to ...

Pop quiz: would you prefer to take a medication as a pill or inject yourself with it? Somehow, I suspect that the vast majority of people would prefer the latter option. As GLP-1 drugs like Wegovy and ...

Merck is injecting $1 billion into a new facility in Wilmington, Delaware to amp up U.S. drug production, especially for its ...